Osteoporosis Update From the 2010 Santa Fe Bone Symposium

Journal of Clinical Densitometry

Volumn 14, Issue 1, 2011, Pages 1-21

  Lewiecki, E Michael ^a   Bilezikian, John P ^b   Khosla, Sundeep ^c   Marcus, Robert ^d   McClung, Michael R ^e   Miller, Paul D ^f   Watts, Nelson B ^g   Maricic, Michael ^h  

^a NEW MEXICO CLINICAL RESEARCH AND OSTEOPOROSIS CENTER   (United States)

^b Columbia University College of Physicians and Surgeons ^*  (United States)

^c MAYO CLINIC   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e OREGON OSTEOPOROSIS CENTER   (United States)

^f University of Colorado Health Sciences Center   (United States)

^g UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^h Catalina Pointe Rheumatology   (United States)

Author keywords

Bisphosphonate; Denosumab; Emerging; Fracture; Osteoporosis

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; DENOSUMAB; ESTROGEN DERIVATIVE; IBANDRONIC ACID; ODANACATIB; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; SEROTONIN ANTAGONIST; ZOLEDRONIC ACID;

BONE FRAGILITY; CLINICAL PRACTICE; DUAL ENERGY X RAY ABSORPTIOMETRY; ESOPHAGUS CANCER; FEMUR SHAFT FRACTURE; FRACTURE HEALING; HEART ATRIUM FIBRILLATION; HUMAN; JAW OSTEONECROSIS; KIDNEY DISEASE; MEDICAL RESEARCH; MUSCULOSKELETAL PAIN; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; UNITED STATES; WORLD HEALTH ORGANIZATION;

ABSORPTIOMETRY, PHOTON; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; COMBINED MODALITY THERAPY; CONGRESSES AS TOPIC; DIPHOSPHONATES; FEMALE; FRACTURES, BONE; HUMANS; MALE; OSTEOPOROSIS; POSTMENOPAUSE; RISK ASSESSMENT; UNITED STATES;

EID: 79551481740     PISSN: 10946950     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jocd.2010.12.001     Document Type: Review

References (168)

1. Lewiecki E.M., Baim S., Bilezikian J.P., et al. 2008 Santa Fe Bone Symposium: update on osteoporosis. J Clin Densitom 2009, 12(2):135-157.
2. Lewiecki E.M., Bilezikian J.P., Cooper C., et al. Proceedings of the Eighth Annual Santa Fe Bone Symposium, August 3-4, 2007. J Clin Densitom 2008, 11(2):313-324.
3. Lewiecki E.M. 2006 Proceedings of the Santa Fe Bone Symposium. Womens Health 2006, 2(6):825-828.
4. Lewiecki E.M., Bilezikian J.P., Laster A.J., et al. 2009 Santa Fe Bone symposium. J Clin Densitom 2010, 13(1):1-9.
5. Bilezikian J.P. Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis. Am J Med 2009, 122(2 Suppl):S14-S21.
6. Recker R.R., Lewiecki E.M., Miller P.D., Reiffel J. Safety of bisphosphonates in the treatment of osteoporosis. Am J Med 2009, 122(2 Suppl):S22-S32.
7. Russell R.G., Watts N.B., Ebetino F.H., Rogers M.J. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008, 19(6):733-759.
8. Bilezikian J.P., Matsumoto T., Bellido T., et al. Targeting bone remodeling for the treatment of osteoporosis: summary of the proceedings of an ASBMR workshop. J Bone Miner Res 2009, 24(3):373-385.
9. Canalis E., Giustina A., Bilezikian J.P. Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 2007, 357(9):905-916.
10. Bilezikian JP, Rubin MR. 2006 Monitoring anabolic treatment. In: Dynamics of Bone and Cartilage Metabolism. Vol. 2. Seibel MJ, Robins SP, Bilezikian JP, eds. Elsevier Academic Press, San Diego, CA, 629-647.
11. Neer R.M., Arnaud C.D., Zanchetta J.R., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 344:1434-1441.
12. Greenspan S.L., Bone H.G., Ettinger M.P., et al. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med 2007, 146(5):326-339.
13. Bilezikian J.P. Clinical use of parathyroid hormone in osteoporosis. Osteoporosis-Pathophysiology and Clinical Management 2010, 511-526. Humana Press, New York City, NY. 2nd ed.
14. Ettinger B., San M.J., Crans G., Pavo I. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 2004, 19(5):745-751.
15. Miller P.D., Delmas P.D., Lindsay R., et al. Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J Clin Endocrinol Metab 2008, 93(10):3785-3793.
16. Kurland E.S., Heller S.L., Diamond B., et al. The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone (1-34)]. Osteoporos Int 2004, 15(12):992-997.
17. Black D.M., Bilezikian J.P., Ensrud K.E., et al. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med 2005, 353(6):555-565.
18. Black D.M., Greenspan S.L., Ensrud K.E., et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003, 349(13):1207-1215.
19. Finkelstein J.S., Hayes A., Hunzelman J.L., et al. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 2003, 349(13):1216-1226.
20. Deal C., Omizo M., Schwartz E.N., et al. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J Bone Miner Res 2005, 20(11):1905-1911.
21. Cosman F, Eriksen EF, Recknor C, et al. 2010 Effects of intravenous zoledronic acid plus subcutaneous teriparatide [(1-34)rhPTH] in postmenopausal osteoporosis. J Bone Miner Res 2010 Sep 2 [Epub ahead of print] PMID: 20814967.
22. Cosman F., Nieves J., Zion M., et al. Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med 2005, 353(6):566-575.
23. Cosman F., Nieves J.W., Zion M., et al. Retreatment with teriparatide one year after the first teriparatide course in patients on continued long-term alendronate. J Bone Miner Res 2009, 24(6):1110-1115.
24. Finkelstein J.S., Wyland J.J., Lee H., Neer R.M. Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. J Clin Endocrinol Metab 2010, 95(4):1838-1845.
25. Cosman F., Wermers R.A., Recknor C., et al. Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent. J Clin Endocrinol Metab 2009, 94(10):3772-3780.
26. Miller P.D. Denosumab: anti-RANKL antibody. Curr Osteoporos Rep 2009, 7(1):18-22.
27. McClung M.R., Lewiecki E.M., Cohen S.B., et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006, 354(8):821-831.
28. Miller P.D., Bolognese M.A., Lewiecki E.M., et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 2008, 43(2):222-229.
29. Lewiecki E.M., Miller P.D., McClung M.R., et al. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low bone mineral density. J Bone Miner Res 2007, 22:1832-1841.
30. Cummings S.R., San Martin J., McClung M.R., et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009, 361(8):756-765.
31. Pennypacker B., Shea M., Liu Q., et al. Bone density, strength, and formation in adult cathepsin K (-/-) mice. Bone 2009, 44(2):199-207.
32. Lewiecki E.M. Odanacatib, a cathepsin K inhibitor for the treatment of osteoporosis and other skeletal disorders associated with excessive bone remodeling. IDrugs 2009, 12(12):799-809.
33. Bone H.G., McClung M.R., Roux C., et al. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J Bone Miner Res 2010, 25(5):937-947.
34. Cosman F., Lane N.E., Bolognese M.A., et al. Effect of transdermal teriparatide administration on bone mineral density in postmenopausal women. J Clin Endocrinol Metab 2010, 95(1):151-158.
35. Fitzpatrick L.A., Brennen E., Kumar S., et al. Ronacaleret, a novel calcium-sensing receptor antagonist, demonstrates potential as an oral bone-forming therapy in healthy postmenopausal women. J Bone Miner Res 2008, 23(Suppl 1):S50.
36. Fitzpatrick L., Dabrowski C., Cicconetti G., et al. Ronacaleret, a calcium-sensing receptor antagonist: results of a 1 year double-blind, placebo-controlled, dose-ranging phase II study. J Bone Miner Res 2009, 24(Suppl 1). Available at:, Accessed: August 20, 2010. http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx%3Faid%3Da2c9cbad-2834-4a51-9b49-032e01e0f10c.
37. Horwitz M.J., Tedesco M.B., Garcia-Ocana A., et al. Parathyroid hormone-related protein for the treatment of postmenopausal osteoporosis: defining the maximal tolerable dose. J Clin Endocrinol Metab 2010, 95(3):1279-1287.
38. O'Brien C.A., Plotkin L.I., Galli C., et al. Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS One 2008, 3(8):e2942.
39. Silvestrini G., Ballanti P., Leopizzi M., et al. Effects of intermittent parathyroid hormone (PTH) administration on SOST mRNA and protein in rat bone. J Mol Histol 2007, 38(4):261-269.
40. Mirza F.S., Padhi I.D., Raisz L.G., Lorenzo J.A. Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J Clin Endocrinol Metab 2010, 95(4):1991-1997.
41. Kousteni S., Bilezikian J.P. The cell biology of parathyroid hormone in osteoblasts. Curr Osteoporos Rep 2008, 6(2):72-76.
42. Hoeppner L.H., Secreto F.J., Westendorf J.J. Wnt signaling as a therapeutic target for bone diseases. Expert Opin Ther Targets 2009, 13(4):485-496.
43. Li X., Ominsky M.S., Warmington K.S., et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 2009, 24(4):578-588.
44. Yadav V.K., Ducy P. Lrp5 and bone formation: a serotonin-dependent pathway. Ann N Y Acad Sci 2010, 1192(1):103-109.
45. Frost M., Andersen T.E., Yadav V., et al. Patients with high-bone-mass phenotype owing to Lrp5-T253I mutation have low plasma levels of serotonin. J Bone Miner Res 2010, 25(3):673-675.
46. Yadav V.K., Balaji S., Suresh P.S., et al. Pharmacological inhibition of gut-derived serotonin synthesis is a potential bone anabolic treatment for osteoporosis. Nat Med 2010, 16(3):308-312.
47. Laib A., Ruegsegger P. Calibration of trabecular bone structure measurements of in vivo three-dimensional peripheral quantitative computed tomography with 28-microm-resolution microcomputed tomography. Bone 1999, 24(1):35-39.
48. Bailey D.A., Wedge J.H., McCulloch R.G., et al. Epidemiology of fractures of the distal end of the radius in children as associated with growth. J Bone Joint Surg [Am] 1989, 71(8):1225-1231.
49. Khosla S., Melton L.J., Dekutoski M.B., et al. Incidence of childhood distal forearm fractures over 30 years: a population-based study. JAMA 2003, 290(11):1479-1485.
50. Kirmani S., Christen D., van Lenthe G.H., et al. Bone structure at the distal radius during adolescent growth. J Bone Miner Res 2009, 24(6):1033-1042.
51. Khosla S., Riggs B.L., Atkinson E.J., et al. Effects of sex and age on bone microstructure at the ultradistal radius: a population-based noninvasive in vivo assessment. J Bone Miner Res 2006, 21(1):124-131.
52. Melton L.J., Christen D., Riggs B.L., et al. Assessing forearm fracture risk in postmenopausal women. Osteoporos Int 2010, 21(7):1161-1169.
53. Melton L.J., Riggs B.L., Keaveny T.M., et al. Relation of vertebral deformities to bone density, structure and strength. J Bone Miner Res 2010, 25(9):1922-1930.
54. Kristiansen T.K., Ryaby J.P., McCabe J., et al. Accelerated healing of distal radial fractures with the use of specific, low-intensity ultrasound. A multicenter, prospective, randomized, double-blind, placebo-controlled study. J Bone Joint Surg [Am] 1997, 79(7):961-973.
55. Govender S., Csimma C., Genant H.K., et al. Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients. J Bone Joint Surg [Am] 2002, 84-A(12):2123-2134.
56. Rozental T.D., Vazquez M.A., Chacko A.T., et al. Comparison of radiographic fracture healing in the distal radius for patients on and off bisphosphonate therapy. J Hand Surg [Am] 2009, 34(4):595-602.
57. Alharbi M., Pinto G., Finidori G., et al. Pamidronate treatment of children with moderate-to-severe osteogenesis imperfecta: a note of caution. Horm Res 2009, 71(1):38-44.
58. Andreassen T.T., Ejersted C., Oxlund H. Intermittent parathyroid hormone (1-34) treatment increases callus formation and mechanical strength of healing rat fractures. J Bone Miner Res 1999, 14(6):960-968.
59. O'Loughlin P.F., Cunningham M.E., Bukata S.V., et al. Parathyroid hormone (1-34) augments spinal fusion, fusion mass volume, and fusion mass quality in a rabbit spinal fusion model. Spine 2009, 34(2):121-130.
60. Aspenberg P., Genant H.K., Johansson T., et al. Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res 2010, 25(2):404-414.
61. Cauley J.A., Robbins J., Chen Z., et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 2003, 290(13):1729-1738.
62. Schousboe J.T., Nyman J.A., Kane R.L., Ensrud K.E. Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women. Ann Intern Med 2005, 142(9):734-741.
63. National Osteoporosis Foundation Clinician's guide to prevention and treatment of osteoporosis 2008, National Osteoporosis Foundation, Washington, DC.
64. Wainwright S.A., Marshall L.M., Ensrud K.E., et al. Hip fracture in women without osteoporosis. J Clin Endocrinol Metab 2005, 90(5):2787-2793.
65. Recker R., Lappe J., Davies K., Heaney R. Characterization of perimenopausal bone loss: a prospective study. J Bone Miner Res 2000, 15(10):1965-1973.
66. Finkelstein J.S., Brockwell S.E., Mehta V., et al. Bone mineral density changes during the menopause transition in a multiethnic cohort of women. J Clin Endocrinol Metab 2008, 93(3):861-868.
67. Bush T.L., Wells H.B., James M.K., et al. Effects of hormone therapy on bone mineral density-results from the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 1996, 276:1389-1396.
68. Hosking D., Chilvers C.E.D., Christiansen C., et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. N Engl J Med 1998, 338(8):485-492.
69. Lindsay R., Hart D.M., MacLean A., et al. Bone response to termination of oestrogen treatment. Lancet 1978, 1:1325-1327.
70. Wasnich R.D., Bagger Y.Z., Hosking D.J., et al. Changes in bone density and turnover after alendronate or estrogen withdrawal. Menopause 2004, 11(6 Pt 1):622-630.
71. McClung M., Miller P., Recknor C., et al. Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized controlled trial. Obstet Gynecol 2009, 114(5):999-1007.
72. McClung M., Clemmesen B., Daifotis A., et al. Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group. Ann Intern Med 1998, 128(4):253-261.
73. Ravn P., Weiss S., Rodriguez-Portales J.A., et al. Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. J Clin Endocrinol Metab 2000, 85:1942-1947.
74. Ascott-Evans B.H., Guanabens N., Kivinen S., et al. Alendronate prevents loss of bone density associated with discontinuation of hormone replacement therapy: a randomized controlled trial. Arch Intern Med 2003, 163(7):789-794.
75. Confavreux C.B., Fontana A., Guastalla J.P., et al. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates. Bone 2007, 41(3):346-352.
76. Shahinian V.B., Kuo Y.F., Freeman J.L., Goodwin J.S. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005, 352(2):154-164.
77. Hershman D.L., McMahon D.J., Crew K.D., et al. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol 2008, 26(29):4739-4745.
78. Smith M.R., McGovern F.J., Zietman A.L., et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001, 345(13):948-955.
79. Smith M.R., Eastham J., Gleason D.M., et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003, 169(6):2008-2012.
80. Greenspan S.L., Nelson J.B., Trump D.L., Resnick N.M. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med 2007, 146(6):416-424.
81. Smith M.R., Egerdie B., Hernandez T.N., et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009, 361(8):745-755.
82. Gilchrist N.L., Frampton C.M., Acland R.H., et al. Alendronate prevents bone loss in patients with acute spinal cord injury: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 2007, 92(4):1385-1390.
83. National Osteoporosis Foundation Physician's guide to prevention and treatment of osteoporosis 2003, National Osteoporosis Foundation, Washington, DC.
84. Kanis J.A., Borgstrom F., De Laet C., et al. Assessment of fracture risk. Osteoporos Int 2005, 16(6):581-589.
85. McClung M. Assessing fracture risk in individual patients. J Watch Womens Health 2008, 12:69-70.
86. Hodgson S.F., Watts N.B. The 2001 AACE medical guidelines for clinical practice for the prevention and management of postmenopausal osteoporosis. Endocr Pract 2001, 7:293-312.
87. Tannenbaum C., Clark J., Schwartzman K., et al. Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. J Clin Endocrinol Metab 2003, 87:4431-4437.
88. Worcester E.M., Coe F.L. Clinical practice. Calcium kidney stones. N Engl J Med 2010, 363(10):954-963.
89. Consensus conference Prevention and treatment of kidney stones. J Am Med Assoc 1988, 260(7):977-981.
90. Coe F.L., Bushinsky D.A. Pathophysiology of hypercalciuria. Am J Physiol 1984, 247(1 Pt 2):F1-F13.
91. Asplin J.R., Bauer K.A., Kinder J., et al. Bone mineral density and urine calcium excretion among subjects with and without nephrolithiasis. Kidney Int 2003, 63(2):662-669.
92. Pietschmann F., Breslau N.A., Pak C.Y.C. Reduced vertebral bone density in hypercalciuric nephrolithiasis. J Bone Miner Res 1992, 7:1383-1388.
93. Jaeger P., Lippuner K., Casez J.P., et al. Low bone mass in idiopathic renal stone formers: magnitude and significance. J Bone Miner Res 1994, 9(10):1525-1532.
94. Giannini S., Nobile M., Sartori L., et al. Bone density and skeletal metabolism are altered in idiopathic hypercalciuria. Clin Nephrol 1998, 50(2):94-100.
95. Da Silva A.M.M., Dos Reis L.M., Pereira R.C., et al. Bone involvement in idiopathic hypercalciuria. Clin Nephrol 2002, 57(3):183-191.
96. Tasca A., Cacciola A., Ferrarese P., et al. Bone alterations in patients with idiopathic hypercalciuria and calcium nephrolithiasis. Urology 2002, 59(6):865-869.
97. Pak C.Y., Kaplan R., Bone H., et al. A simple test for the diagnosis of absorptive, resorptive and renal hypercalciurias. N Engl J Med 1975, 292(10):497-500.
98. Grynpas M., Waldman S., Holmyard D., Bushinsky D.A. Genetic hypercalciuric stone-forming rats have a primary decrease in BMD and strength. J Bone Miner Res 2009, 24(8):1420-1426.
99. Bilezikian J.P., Khan A.A., Potts J.T. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab 2009, 94(2):335-339.
100. Christensen S.E., Nissen P.H., Vestergaard P., et al. Plasma 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and parathyroid hormone in familial hypocalciuric hypercalcemia and primary hyperparathyroidism. Eur J Endocrinol 2008, 159(6):719-727.
101. Fuleihan G.E. Familial benign hypocalciuric hypercalcemia. J Bone Miner Res 2002, 17:N51-N56.
102. Levey A.S., Atkins R., Coresh J., et al. Chronic kidney disease as a global public health problem: approaches and initiatives-a position statement from Kidney Disease Improving Global Outcomes. Kidney Int 2007, 72(3):247-259.
103. Kidney Disease: Improving Global Outcomes (KDIGO) KDIGO guideline for chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int 2009, 113(Suppl):S1-S130.
104. Bida J.P., Kyle R.A., Therneau T.M., et al. Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients. Mayo Clin Proc 2009, 84(8):685-693.
105. Varettoni M., Corso A., Cocito F., et al. Changing pattern of presentation in monoclonal gammopathy of undetermined significance: a single-center experience with 1400 patients. Medicine (Baltimore) 2010, 89(4):211-216.
106. van der Windt D.A., Jellema P., Mulder C.J., et al. Diagnostic testing for celiac disease among patients with abdominal symptoms: a systematic review. JAMA 2010, 303(17):1738-1746.
107. Civitelli R., Armamento-Villareal R., Napoli N. Bone turnover markers: understanding their value in clinical trials and clinical practice. Osteoporos Int 2009, 20(6):843-851.
108. Baim S., Miller P.D. Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw. J Bone Miner Res 2009, 24(4):561-574.
109. Glover S.J., Gall M., Schoenborn-Kellenberger O., et al. Establishing a reference interval for bone turnover markers in 637 healthy, young, premenopausal women from the United Kingdom, France, Belgium, and the United States. J Bone Miner Res 2009, 24(3):389-397.
110. Srivastava A.K., Vliet E.L., Lewiecki E.M., et al. Clinical use of serum and urine bone markers in the management of osteoporosis. Curr Med Res Opin 2005, 21(7):1015-1026.
111. Bergmann P., Body J.J., Boonen S., et al. Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club. Int J Clin Pract 2009, 63(1):19-26.
112. Ivaska K.K., Gerdhem P., Vaananen H.K., et al. Bone turnover markers and prediction of fracture: a prospective follow-up study of 1040 elderly women for a mean of 9 years. J Bone Miner Res 2010, 25(2):393-403.
113. Miller P., Bolognese M., Lewiecki E., et al. Effects of denosumab on bone mineral density and biochemical markers of bone turnover: 6 year results of a phase 2 clinical trial. J Bone Miner Res 2009, 24(Suppl 1). Available at:, Accessed: October 23, 2009. http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx%3Faid%3D1cf516b5-29be-4edf-b1ed-7fa92b4f2031.
114. Pazianas M., Abrahamsen B. Safety of bisphosphonates. Bone 2010, 43(Suppl):222-229.
115. Chen P., Satterwhite J.H., Licata A.A., et al. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 2005, 20(6):962-970.
116. Glover S.J., Eastell R., McCloskey E.V., et al. Rapid and robust response of biochemical markers of bone formation to teriparatide therapy. Bone 2009, 45(6):1053-1058.
117. Bonnick S.L., Shulman L. Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both?. Am J Med 2006, 119(4 Suppl 1):S25-S31.
118. Miller P.D. Monitoring osteoporosis therapies. Curr Osteoporos Rep 2007, 5(1):38-43.
119. Imel E.A., Econs M.J. Fibroblast growth factor 23: roles in health and disease. J Am Soc Nephrol 2005, 16(9):2565-2575.
120. Juppner H., Wolf M., Salusky I.B. FGF-23: More than a regulator of renal phosphate handling?. J Bone Miner Res 2010, 25(10):2091-2097.
121. Parfitt A.M., Drezner M.K., Glorieux F.H., et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 1987, 2(6):595-610.
122. Miller P.D. The role of bone biopsy in patients with chronic renal failure. Clin J Am Soc Nephrol 2008, 3(Suppl 3):S140-S150.
123. Rauch F. Bone biopsy: indications and methods. Endocr Dev 2009, 16:49-57.
124. Adami S., Bhalla A.K., Dorizzi R., et al. The acute phase response after bisphosphonate administration. Calcif Tissue Int 1987, 41:326-331.
125. Gallacher S.J., Ralston S.H., Patel U., Boyle I.T. Side-effects of pamidronate. Lancet 1989, 2:42-43.
126. Zojer N., Keck A.V., Pecherstorfer M. Comparative tolerability of drug therapies for hypercalcaemia of malignancy. Drug Saf 1999, 21(5):389-406.
127. Maalouf N.M., Heller H.J., Odvina C.V., et al. Bisphosphonate-induced hypocalcemia: report of 3 cases and review of literature. Endocr Pract 2006, 12(1):48-53.
128. Marx R.E. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003, 61(9):1115-1117.
129. Ruggiero S.L., Mehrotra B., Rosenberg T.J., Engroff S.L. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004, 62(5):527-534.
130. Woo S.B., Hellstein J.W., Kalmar J.R. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006, 144(10):753-761.
131. Khosla S., Burr D., Cauley J., et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007, 22(10):1479-1489.
132. Black D.M., Delmas P.D., Eastell R., et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007, 356(18):1809-1822.
133. U.S.Food and Drug Administration Update of safety review follow-up to the October 1, 2007. Early communication about the ongoing safety review of bisphosphonates 2008, U.S. Food and Drug Administration, Rockville, MD. Available at:, Accessed: March 24, 2010. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm136201.htm.
134. Wysowski D.K. Reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009, 360(1):89-90.
135. Siris E.S., Oster M.W., Bilezikian J.P. More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009, 360(17):1791. [Letter].
136. Solomon D.H., Patrick A., Brookhart M.A. More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009, 360(17):1789-1790. [Letter].
137. Abrahamsen B., Eiken P., Eastell R. More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009, 360(17):1789. [Letter].
138. Wysowski D.K., Chang J.T. Alendronate and risedronate: reports of severe bone, joint, and muscle pain. Arch Intern Med 2005, 165(3):346-347.
139. Miller P.D. Treatment of osteoporosis in chronic kidney disease and end-stage renal disease. Curr Osteoporos Rep 2005, 3(1):5-12.
140. Miller P.D., Roux C., Boonen S., et al. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res 2005, 20(12):2105-2115.
141. Jamal S.A., Bauer D.C., Ensrud K.E., et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. J Bone Miner Res 2007, 22(4):503-508.
142. Lyles K.W., Colon-Emeric C.S., Magaziner J.S., et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007, 357(18):1799-1809.
143. Lewiecki E.M., Miller P.D. Renal safety of intravenous bisphosphonates in the treatment of osteoporosis. Expert Opin Drug Saf 2007, 6(6):663-672.
144. Eisman J.A., Civitelli R., Adami S., et al. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheumatol 2008, 35(3):488-497.
145. Miller P., Leigh C., Ward P. Renal tolerability of intravenous ibandronate allows administration by short injection. Ann Rheum Dis 2006, 65(Suppl 2):422.
146. Boonen S., Sellmeyer D.E., Lippuner K., et al. Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney Int 2008, 74(5):641-648.
147. Miller P.D. Diagnosis and treatment of osteoporosis in chronic renal disease. Semin Nephrol 2009, 29(2):144-155.
148. Mashiba T., Hirano T., Turner C.H., et al. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 2000, 15(4):613-620.
149. Odvina C.V., Zerwekh J.E., Rao D.S., et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005, 90(3):1294-1301.
150. Visekruna M., Wilson D., McKiernan F.E. Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab 2008, 93(8):2948-2952.
151. Armamento-Villareal R., Napoli N., Diemer K., et al. Bone turnover in bone biopsies of patients with low-energy cortical fractures receiving bisphosphonates: a case series. Calcif Tissue Int 2009, 85(1):37-44.
152. Capeci C.M., Tejwani N.C. Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy. J Bone Joint Surg [Am] 2009, 91(11):2556-2561.
153. Odvina C.V., Levy S., Rao S., et al. Unusual mid-shaft fractures during long-term bisphosphonate therapy. Clin Endocrinol (Oxf) 2010, 72(2):161-168.
154. Goh S.K., Yang K.Y., Koh J.S., et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg [Br] 2007, 89(3):349-353.
155. Neviaser A.S., Lane J.M., Lenart B.A., et al. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 2008, 22(5):346-350.
156. Lenart B.A., Neviaser A.S., Lyman S., et al. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int 2009, 20(8):1353-1362.
157. Abrahamsen B., Eiken P., Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 2009, 24(6):1095-1102.
158. Black D.M., Kelly M.P., Genant H.K., et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 2010, 362(19):1761-1771.
159. Shane E., Burr D., Ebeling P.R., et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010, 25(11):2267-2294.
160. Bone H.G., Hosking D., Devogelaer J.P., et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004, 350(12):1189-1199.
161. Black D.M., Schwartz A.V., Ensrud K.E., et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006, 296(24):2927-2938.
162. Watts N.B., Chines A., Olszynski W.P., et al. Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int 2008, 19(3):365-372.
163. Mellstrom D.D., Sorensen O.H., Goemaere S., et al. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 2004, 75(6):462-468.
164. Schwartz A.V., Bauer D.C., Cummings S.R., et al. Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J Bone Miner Res 2010, 25(5):976-982.
165. Kennel K.A., Drake M.T. Adverse effects of bisphosphonates: implications for osteoporosis management. Mayo Clin Proc 2009, 84(7):632-637.
166. U.S.Food and Drug Administration, FDA FDA Drug Safety Communication: ongoing safety review of oral bisphosphonates and atypical subtrochanteric femur fractures 2010, U.S. Food and Drug Administration, Rockville, MD. Available at:, Accessed: March 23, 2010. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm203891.htm.
167. Somford M.P., Draijer F.W., Thomassen B.J., et al. Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long-term treatment with alendronate: clues to the mechanism of increased bone fragility. J Bone Miner Res 2009, 24(10):1736-1740.
168. Mishra A., Wong L., Jonklaas J. Prolonged, symptomatic hypocalcemia with pamidronate administration and subclinical hypoparathyroidism. Endocrine 2001, 14(2):159-164.